Han Wang, Junrui Ma, Jiagui Lu, Yang Wang, Binli Zhang, Hushan Zhang, Hao Peng
{"title":"在宣威，TMB与egfr突变的非小细胞肺癌的预后相关。","authors":"Han Wang, Junrui Ma, Jiagui Lu, Yang Wang, Binli Zhang, Hushan Zhang, Hao Peng","doi":"10.1080/17520363.2024.2432306","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Study on the prognostic characteristics and biomarkers of lung cancer in Xuanwei Patients.</p><p><strong>Materials and methods: </strong>A retrospective analysis was conducted on the genetic data of 261 NSCLC patients, as well as the prognostic data of 133 patients. The relationship between prognosis and EGFR mutations in the Xuanwei and non Xuanwei cohorts was compared and analyzed.</p><p><strong>Results: </strong>The superior progression-free survival (PFS) in Xuanwei patients was primarily observed in those with EGFR-mutated tumors (<i>p</i> < 0.05). Further analysis of accompanying mutations and TMB levels revealed an association between high TMB and a favorable prognosis in EGFR-mutated Xuanwei NSCLC.</p><p><strong>Conclusion: </strong>Xuanwei lung cancer differs from non Xuanwei patients in terms of prognosis and tumor mutation burden, and further research should be conducted.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1123-1133"},"PeriodicalIF":1.9000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11654810/pdf/","citationCount":"0","resultStr":"{\"title\":\"TMB is associated with the prognosis of egfr-mutated non-small cell lung cancer in Xuanwei, China.\",\"authors\":\"Han Wang, Junrui Ma, Jiagui Lu, Yang Wang, Binli Zhang, Hushan Zhang, Hao Peng\",\"doi\":\"10.1080/17520363.2024.2432306\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>Study on the prognostic characteristics and biomarkers of lung cancer in Xuanwei Patients.</p><p><strong>Materials and methods: </strong>A retrospective analysis was conducted on the genetic data of 261 NSCLC patients, as well as the prognostic data of 133 patients. The relationship between prognosis and EGFR mutations in the Xuanwei and non Xuanwei cohorts was compared and analyzed.</p><p><strong>Results: </strong>The superior progression-free survival (PFS) in Xuanwei patients was primarily observed in those with EGFR-mutated tumors (<i>p</i> < 0.05). Further analysis of accompanying mutations and TMB levels revealed an association between high TMB and a favorable prognosis in EGFR-mutated Xuanwei NSCLC.</p><p><strong>Conclusion: </strong>Xuanwei lung cancer differs from non Xuanwei patients in terms of prognosis and tumor mutation burden, and further research should be conducted.</p>\",\"PeriodicalId\":9182,\"journal\":{\"name\":\"Biomarkers in medicine\",\"volume\":\" \",\"pages\":\"1123-1133\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11654810/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers in medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17520363.2024.2432306\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/5 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2024.2432306","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
TMB is associated with the prognosis of egfr-mutated non-small cell lung cancer in Xuanwei, China.
Aims: Study on the prognostic characteristics and biomarkers of lung cancer in Xuanwei Patients.
Materials and methods: A retrospective analysis was conducted on the genetic data of 261 NSCLC patients, as well as the prognostic data of 133 patients. The relationship between prognosis and EGFR mutations in the Xuanwei and non Xuanwei cohorts was compared and analyzed.
Results: The superior progression-free survival (PFS) in Xuanwei patients was primarily observed in those with EGFR-mutated tumors (p < 0.05). Further analysis of accompanying mutations and TMB levels revealed an association between high TMB and a favorable prognosis in EGFR-mutated Xuanwei NSCLC.
Conclusion: Xuanwei lung cancer differs from non Xuanwei patients in terms of prognosis and tumor mutation burden, and further research should be conducted.
期刊介绍：
Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.
Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.
As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.
Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.
Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
